The latest price target for Ocuphire Pharma (NASDAQ:OCUP) was reported by HC Wainwright & Co. on August 15, 2024. The analyst firm set a price target for $18.00 expecting OCUP to rise to within 12 months (a possible 1263.64% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Ocuphire Pharma (NASDAQ:OCUP) was provided by HC Wainwright & Co., and Ocuphire Pharma maintained their buy rating.

There is no last upgrade for Ocuphire Pharma

There is no last downgrade for Ocuphire Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocuphire Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocuphire Pharma was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.

While ratings are subjective and will change, the latest Ocuphire Pharma (OCUP) rating was a maintained with a price target of $20.00 to $18.00. The current price Ocuphire Pharma (OCUP) is trading at is $1.32, which is out of the analyst’s predicted range.